# US 2010/0168064 A1 · Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168064 A1
- Document ID: US20100168064A1
- Status: Published application
- Kind: A1
- Application number: 12/448,088
- Filed: 2007-12-07
- Published: 2010-07-01
- Earliest claimed: 2006-12-07
- Assignees: China Medical University
- Inventors: Sheng-Chu Kuo; Che-Ming Teng; Kuo-Hsiung Lee; Li-Jiau Huang; Li-Chen Chou; Chih-Shiang Chang; Chung-Ming Sun; Tian-Shung Wu; Shiow-Lin Pan; Tzong-Der Way; Jang-Chang Lee; Jing-Gung Chung; Jai-Sing Yang; Chien-Ting Chen; Ching-Che Huang; Shih-Ming Huang
- Web page: https://patentgrep.com/patent/US20100168064A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 215/233: only one oxygen atom which is attached in position 4
- C07D 421/04: directly linked by a ring-member-to-ring-member bond
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07F 9/60: Quinoline or hydrogenated quinoline ring systems
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and Λ/, Λ/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

## Claims

### Claim 1

A phosphate derivative of 2-aryl-4-quinolone having the following formulas Ia, Ib or Ic:
wherein
R2′, R3′, R4′, R5′ and R6′ independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4;
R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
or R3 and R4 together is —Y(CH2)nY—, wherein n, Y, X, R8 and R9 are defined as above; and
R1 and R1′ independently are H, Li+, Na+, K+, N+R8R9R10R11 or benzyl wherein R10 and R11 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1) or (CH2)nCH3, n, m, R8 and R9 are defined as above.

### Claim 2 (depends on 1)

The phosphate derivative according to claim 1, which has the formula Ia.

### Claim 3 (depends on 2)

The phosphate derivative according to claim 2, wherein R2′, R3′, R4′, R5′ and R6′ are all H; or one of R2′, R3′, R4′, R5′ and R6′ is F, OCH3 or (CH2)nNR8R9, and the others thereof are H, wherein R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2n+1) or (Ch2)nCH3.
wherein n is an integer of O-4, Y is O or S, and m is an integer of 0-4.

### Claim 4 (depends on 2)

The phosphate derivative according to claim 2, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4, and R5 is F, OCH3, Y(CH2)nCH3 or (CH2)nNR8R9, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is —O(CH2)nO—, wherein R8 and R9. independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2n+1) or (Ch2)nCH3.
wherein n is an integer of O-4, Y is O or S, and m is an integer of 0-4.

### Claim 5 (depends on 2)

The phosphate derivative according to claim 2, wherein R1 and R1′ are both H or both Na+.

### Claim 6 (depends on 5)

The phosphate derivative according to claim 5, wherein R2 and R5 are H, and R3 and R4 together is —O(CH2)O—; and R2′, R3′, R4′ and R5′ are all H, and R6′ is F.

### Claim 7 (depends on 5)

The phosphate derivative according to claim 5, wherein R2 and R5 are H, and R3 and R4 together is —O(CH2)O—; and R2′, R3′, R4′ and R6′ are all H, and R5′ is F.

### Claim 8 (depends on 5)

The phosphate derivative according to claim 5, wherein R4 is F, and R2, R3 and R5 are H; and R2′, R3′, R4′, R5′ and R6′ are all H.

### Claim 9 (depends on 5)

The phosphate derivative according to claim 5, wherein R2, R3, R4 and R5 are all H; and R2′, R3′, R4′, R5′ and R6′ are all H.

### Claim 10 (depends on 5)

The phosphate derivative according to claim 5, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5′ is F, and R2′, R3′, R4′ and R6′ are H.

### Claim 11 (depends on 5)

The phosphate derivative according to claim 5, wherein R2 and R5 are H, and R3 and R4 together is —O(CH2)O—; and R2′, R3′, R4′ and R6′ are all H, and R5′ is OCH3.

### Claim 12 (depends on 5)

The phosphate derivative according to claim 5, wherein R4 is CH2N(C2H5)2, and R2, R3 and R5 are H; and R6′ is F, and R2′, R3′, R4′ and R5′ are H.

### Claim 13 (depends on 5)

The phosphate derivative according to claim 5, wherein R4 is CH2N(C2H5)2, and R2, R3 and R5 are H; and R2′, R3′, R4′, R5′ and R6′ are all H.

### Claim 14 (depends on 5)

The phosphate derivative according to claim 5, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5′ is CH2N(C2H5)2, and R2′, R3′, R4′ and R6′ are H.

### Claim 15 (depends on 1)

The phosphate derivative according to claim 1, which has the formula Ib.

### Claim 16 (depends on 15)

The phosphate derivative according to claim 15, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4 and R5 is F or OCH3, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is —O(CH2)nO—, wherein n is an integer of O-4.

### Claim 17 (depends on 15)

The phosphate derivative according to claim 15, wherein R2′, R3′ and R4′ are all H; or one of R2′, R3′ and R4′ is F or OCH3, and the others thereof are H.

### Claim 18 (depends on 15)

The phosphate derivative according to claim 15, wherein R1 and R1′ are benzyl.

### Claim 19 (depends on 18)

The phosphate derivative according to claim 18, wherein R2′, R3′, R4′, R2 and R5 are all H, and R3 and R4 together is —O(CH2)O—.

### Claim 20 (depends on 1)

A method for killing solid cancer cells, which comprises administering to a subject a therapeutically effective amount of a phosphate derivative of 2-aryl-4-quinolone as in claim 1 or a pharmaceutically acceptable salt thereof, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer

### Claim 22 (depends on 21)

The method according to claim 21, wherein the solid cancer cells are human breast cancer or colon cancer.

### Claim 23

A compound of 2-selenophene 4-quinolone having the following formulas IIb or IIc:
wherein
R2′, R3′ and R4′ independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, or (CH2)nNR8R9, wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4;
R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
or R3 and R4 together is —Y(CH2)nY—, wherein n, Y, X, R8 and R9 are defined as above.

### Claim 24 (depends on 19, 23)

The compound according to claim 23, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4 and R5 is F or OCH3, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is —O(CH2)nO—, wherein n is defined as in claim 19.

### Claim 25 (depends on 24)

The compound according to claim 24, wherein R2′, R3′ and R4′ are all H; or one of R2′, R3′ and R4′ is F or OCH3, and the others thereof are H.

### Claim 26 (depends on 23)

The compound according to claim 23 which has the formula IIb.

### Claim 27 (depends on 26)

The compound according to claim 26, wherein R2′, R3′, R4′, R2 and R5 are all H, and R3 and R4 together is —O(CH2)O—.

### Claim 28 (depends on 23)

A method for killing solid cancer cells, which comprises administering to a subject a therapeutically effective amount of a compound of 2-selenophene 4-quinolone as in claim 23, or a pharmaceutically acceptable salt thereof, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer.

### Claim 30

A compound of 2-phenyl-4-quinolone having the following formula IIa:
wherein
R2′, R3′, R4′, R5′ and R6′ independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4;
R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
or R3 and R4 together is —Y(CH2)nY—, wherein n, Y, X, R8 and R9 are defined as above;
provided that one of R2, R3, R4 and R5 is (CH2)qNR8R9, or one of R2′, R3′, R4′, R5′ and R6′ is (CH2)qNR8R9, wherein q is an integer of 1-4, and R8 and R9 are defined as above.

### Claim 31 (depends on 30)

The compound according to claim 30, wherein R4 is CH2)qNR8R9, and R2, R3 and R5 are H, wherein q, R8 and R9 are defined as in claim 30.

### Claim 32 (depends on 30)

The compound according to claim 30, wherein R5′ is CH2)qNR8R9, and R2′, R3′, R4′ and R6′ are H, wherein q, R8 and R9 are defined as in claim 30.

### Claim 33 (depends on 31)

The compound according to claim 31, wherein R4 is CH2N(C2H5)2, R6′ is F, and R2′, R3′, R4′ and R6′ are H.

### Claim 34 (depends on 31)

The compound according to claim 31, wherein R4 is CH2N(C2H5)2, R2′, R3′, R4′, R5′ and R6′ are all H.

### Claim 35 (depends on 32)

The compound according to claim 32, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5′ is CH2N(C2H5)2, and R2′, R3′, R4′ and R6′ are H.

### Claim 36 (depends on 30)

A method for killing solid cancer cells, which comprises administering to a subject a therapeutically effective amount of a compound of 2-phenyl 4-quinolone as in claim 30 or a pharmaceutically acceptable salt thereof, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the solid cancer cells are leukemia cancer.
